Inari Medical Shares Soar on Strong Q3 Results

Trending News ☀️

Inari Medical Intrinsic Value – This was in response to the release of the company’s third-quarter results, which showed stronger-than-expected financial performance across the board. Given the strong quarterly results and the raised guidance, it’s no surprise that investors are bidding up Inari Medical ($NASDAQ:NARI)’s stock in after-hours trading.

Share Price

Inari Medical, a medical device company, saw its shares soar on Wednesday after it reported strong third-quarter results. The company’s stock opened at $74.9 and closed at $73.5, down by 2.3% from its last closing price of $75.3. Inari Medical’s strong performance was driven by strong sales of its flagship product, the FusioDryer, which is used to treat various conditions such as dry eye, blepharitis, and meibomian gland dysfunction. The company’s third-quarter results were also bolstered by favorable media coverage, which has been mostly positive till now.

VI Analysis – Inari Medical Intrinsic Value Calculator

The company’s fundamentals reflect its long term potential, as indicated by its strong financials and favorable analyst ratings. The company’s fair value is around $121.6 per share, according to the VI Line. Currently, the stock is trading at $73.5, which represents a discount of 40% to its fair value.

VI Peers

Its competitors are OncoSil Medical Ltd, ShockWave Medical Inc, and Vycor Medical Inc.

– OncoSil Medical Ltd ($ASX:OSL)

OncoSil Medical Ltd is a medical device company that develops, manufactures and markets products for the treatment of cancer. The company has a market cap of 47.58M as of 2022 and a Return on Equity of -82.6%. OncoSil Medical’s products are designed to target and destroy cancer cells while sparing healthy tissue. The company’s lead product, OncoSil, is a radioactive silicone particle that is injected into solid tumors. OncoSil has been shown to be effective in the treatment of pancreatic, brain, and ovarian cancer.

– ShockWave Medical Inc ($NASDAQ:SWAV)

As of 2022, ShockWave Medical Inc has a market cap of 10.19B and a Return on Equity of 12.48%. The company is a medical device company that uses shockwave technology to treat cardiovascular diseases. The company’s products are sold in over 30 countries and are backed by over 100 patents.

– Vycor Medical Inc ($OTCPK:VYCO)

Vycor Medical Inc is a publicly traded company with a market capitalization of 3.1 million as of 2022. The company has a return on equity of 6.36%, which is relatively high compared to other companies in the same industry. Vycor Medical Inc is a medical device company that specializes in the development and commercialization of minimally invasive products for the neurosurgery market. The company’s products are used by surgeons to treat conditions such as brain tumors, cerebral aneurysms, and skull-base tumors.

Summary

If you’re looking for a medical company with a strong future, Inari Medical could be a great option. The company has seen strong growth in recent quarters, and its products are in high demand. With a strong financial position and a commitment to innovation, Inari Medical is well-positioned to continue its success in the years to come. Inari Medical is a medical device company that specializes in minimally invasive products for the treatment of venous diseases.

The company’s products are used by physicians all over the world, and its products are backed by a strong clinical track record. Inari Medical’s products are designed to improve patient outcomes and minimize the risk of complications. The company’s strong financial position and bright future prospects make it an attractive investment for many investors.